Novel Milrinone Nanoformulation for Use in Cardiovascular Diseases: Preparation and in Vitro Characterization

Keyphrases

• Cardiovascular Disease 100%
• In Vitro Characterization 100%
• Milrinone 100%
• Nanoformulation 100%
• Human Serum Albumin Nanoparticles 40%
• Drug Delivery 30%
• Congestive Heart Failure 20%
• Biocompatibility 20%
• Flow Cytometry 10%
• Protease 10%
• Drug Use 10%
• Ethanol 10%
• Mode of Delivery 10%
• Particle Size 10%
• Inpatient Treatment 10%
• Low Cytotoxicity 10%
• Lactate 10%
• Formulation Method 10%
• Non-immunogenic 10%
• Cathepsin D 10%
• Human Umbilical Vein Endothelial Cells (HUVECs) 10%
• Enhanced Bioavailability 10%
• Promising Drug 10%
• Circular Dichroism 10%
• Target Specificity 10%
• Cellular Uptake 10%
• Drug Formulation 10%
• Trypsin 10%
• Pepsin 10%
• Proteinase K 10%
• Zeta Potential 10%
• HUVEC Cells 10%
• Cardiac Repair 10%
• Drug Release Studies 10%
• H9c2 10%
• H9c2 Cells 10%
• Molecular Docking Studies 10%
• In Vitro Release 10%
• Desolvation Process 10%
• Drug Encapsulation Efficiency 10%
• Hydrophobic Cavity 10%
• Intracellular Uptake 10%
• Nanoparticle Toxicity 10%
• Enzyme-like 10%
• Causes of Mortality 10%
• High Viability 10%
• Cardiac Inotrope 10%
• Target-enhanced 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Milrinone 100%
• Cardiovascular Disease 100%
• Nanoformulation 100%
• Nanoparticle 50%
• Human Serum Albumin 40%
• Congestive Heart Failure 20%
• Biocompatibility 20%
• Drug Release 20%
• Flow Cytometry 10%
• Proteinase 10%
• Bioavailability 10%
• Zeta Potential 10%
• Cell Viability 10%
• Inotropic Agent 10%
• Drug Formulation 10%
• Cathepsin D 10%
• Enzymes 10%
• Proteinase K 10%
• Cytotoxicity 10%
• Ethanol 10%